Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays

Proteomics - Clinical Applications

Volumn 4, Issue 10-11, 2010, Pages 794-807

  Dexlin Mellby, Linda ^a   Sandström, Anna ^a   Centlow, Magnus ^a   Nygren, Sara ^a   Hansson, Stefan R ^a   Borrebaeck, Carl A K ^a   Wingren, Christer ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Affinity proteomics; Antibody microarrays; Membrane proteomics; Preeclampsia; Protein expression profiling

Indexed keywords

BIOLOGICAL MARKER; CD40 ANTIGEN; CD40 LIGAND; CELL MEMBRANE PROTEIN; CYTOKINE; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; SIALYL LEWIS X ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; EARLY ONSET PREECLAMPSIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; INTRAUTERINE GROWTH RETARDATION; LATE ONSET PREECLAMPSIA; PARITY; PLACENTA; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEX ROLE;

ADULT; FEMALE; GENE EXPRESSION PROFILING; GESTATIONAL AGE; HUMANS; MIDDLE AGED; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROTEIN ARRAY ANALYSIS; PROTEOME; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 78349288535     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000001     Document Type: Article

References (83)

1. Roberts, J. M., Cooper, D. W., Pathogenesis and genetics of pre-eclampsia. Lancet 2001, 357, 53-56.
2. Mohaupt, M., Molecular aspects of preeclampsia. Mol. Asp. Med. 2007, 28, 169-191.
3. Redman, C. W., Sargent, I. L., Latest advances in understanding preeclampsia. Science 2005, 308, 1592-1594.
4. Duckitt, K., Harrington, D., Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330, 565.
5. Saito, S., Shiozaki, A., Nakashima, A., Sakai, M., Sasaki, Y., The role of the immune system in preeclampsia. Mol. Asp. Med. 2007, 28, 192-209.
6. Sargent, I. L., Borzychowski, A. M., Redman, C. W., Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod. Biomed. Online 2006, 13, 680-686.
7. Borzychowski, A. M., Sargent, I. L., Redman, C. W., Inflammation and pre-eclampsia. Semin. Fetal Neonatal Med. 2006, 11, 309-316.
8. Milne, F., Redman, C., Walker, J., Baker, P. et al., The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005, 330, 576-580.
9. [9] Higgins, J. R., de Swiet, M., Blood-pressure measurement and classification in pregnancy. Lancet 2001, 357, 131-135.
10. Cudihy, D., Lee, R. V., The pathophysiology of pre-eclampsia: current clinical concepts. J. Obstet. Gynaecol. 2009, 29, 576-582.
11. Kanasaki, K., Kalluri, R., The biology of preeclampsia. Kidney Int. 2009, 76, 831-837.
12. Redman, C. W., Immunological aspects of pre-eclampsia. Baillieres Clin. Obstet. Gynaecol. 1992, 6, 601-615.
13. Baker, P. N., Myers, J. E., Preeclamptic toxemia: a disease ripe for proteomic discovery. Exp. Rev. Proteomics 2009, 6, 107-110.
14. Shankar, R., Gude, N., Cullinane, F., Brennecke, S. et al., An emerging role for comprehensive proteome analysis in human pregnancy research. Reproduction 2005, 129, 685-696.
15. Sibai, B., Dekker, G., Kupferminc, M., Pre-eclampsia. Lancet 2005, 365, 785-799.
16. Smets, E. M., Visser, A., Go, A. T., van Vugt, J. M., Oudejans, C. B., Novel biomarkers in preeclampsia. Clin. Chim. Acta 2006, 364, 22-32.
17. Tjoa, M. L., Oudejans, C. B., van Vugt, J. M., Blankenstein, M. A., van Wijk, I. J., Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens. Pregnancy 2004, 23, 171-189.
18. Kharb, S., Serum markers in pre-eclampsia. Biomarkers 2009, 14, 395-400.
19. Aggarwal, N., Suri, V., Soni, S., Chopra, V., Kohli, H. S., A prospective comparison of random urine protein-creatinine ratio vs 24-hour urine protein in women with preeclampsia. Med. J. Med. 2008, 10, 98.
20. Brown, M. A., Buddle, M. L., Hypertension in pregnancy: maternal and fetal outcomes according to laboratory and clinical features. Med. J. Aust. 1996, 165, 360-365.
21. Franceschini, N., Qiu, C., Barrow, D. A., Williams, M. A., Cystatin C and preeclampsia: a case control study. Renal Failure 2008, 30, 89-95.
22. Kharb, S., Total free radical trapping antioxidant potential in pre-eclampsia. Int. J. Gynaecol. Obstet. 2000, 69, 23-26.
23. Kristensen, K., Wide-Swensson, D., Schmidt, C., Blirup-Jensen, S. et al., Cystatin C, beta-2-microglobulin and beta-trace protein in pre-eclampsia. Acta Obstet. Gynaecol. Scand. 2007, 86, 921-926.
24. Grill, S., Rusterholz, C., Zanetti-Dallenbach, R., Tercanli, S. et al., Potential markers of preeclampsia - a review. Reprod. Biol. Endocrinol. 2009, 7, 70.
25. Carty, D. M., Delles, C., Dominiczak, A. F., Novel biomarkers for predicting preeclampsia. Trends Cardio. Med. 2008, 18, 186-194.
26. Levine, R. J., Maynard, S. E., Qian, C., Lim, K. H. et al., Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350, 672-683.
27. Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H. et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111, 649-658.
28. Levine, R. J., Lam, C., Qian, C., Yu, K. F. et al., Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006, 355, 992-1005.
29. Venkatesha, S., Toporsian, M., Lam, C., Hanai, J. et al., Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12, 642-649.
30. Than, N. G., Abdul Rahman, O., Magenheim, R., Nagy, B. et al., Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Arch. 2008, 453, 387-400.
31. Olsson, M. G., Centlow, M., Rutardottir, S., Stenfors, I. et al., Increased levels of cell-free hemoglobin, oxidation markers, and the antioxidative heme scavenger alpha(1)-microglobulin in preeclampsia. Free Radical Biol. Med. 2010, 48, 284-291.
32. Centlow, M., Carninci, P., Nemeth, K., Mezey, E. et al., Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. Fertility Sterility 2008, 90, 1834-1843.
33. Hanash, S., Disease proteomics. Nature 2003, 422, 226-232.
34. Phizicky, E., Bastiaens, P. I., Zhu, H., Snyder, M., Fields, S., Protein analysis on a proteomic scale. Nature 2003, 422, 208-215.
35. Hu, S., Loo, J. A., Wong, D. T., Human body fluid proteome analysis. Proteomics 2006, 6, 6326-6353.
36. Chung, C. H., Levy, S., Chaurand, P., Carbone, D. P., Genomics and proteomics: emerging technologies in clinical cancer research. Crit. Rev. Oncol. Hematol. 2007, 61, 1-25.
37. Borrebaeck, C. A. K., Wingren, C., High-throughput proteomics using antibody microarrays: an update. Exp. Rev. Mol. Diagn. 2007, 7, 673-686.
38. Webster, R. P., Myatt, L., Elucidation of the molecular mechanisms of preeclampsia using proteomic technologies. Proteom. Clin. Appl. 2007, 1, 1147-1155.
39. Blankley, R. T., Gaskell, S. J., Whetton, A. D., Dive, C. et al., A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. BJOG 2009, 116, 1473-1480.
40. Blumenstein, M., McMaster, M. T., Black, M. A., Wu, S. et al., A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 2009, 9, 2929-2945.
41. Jin, H., Ma, K. D., Hu, R., Chen, Y. et al., Analysis of expression and comparative profile of normal placental tissue proteins and those in preeclampsia patients using proteomic approaches. Anal. Chim. Acta 2008, 629, 158-164.
42. Mine, K., Katayama, A., Matsumura, T., Nishino, T. et al., Proteome analysis of human placentae: pre-eclampsia versus normal pregnancy. Placenta 2007, 28, 676-687.
43. Centlow, M., Hansson, S. R., Welinder, C., Differential proteome analysis of the preeclamptic placenta using optimized protein extraction. J. Biomed. Biotech. 2010, 1-9.
44. Gude, N. M., Roberts, C. T., Kalionis, B., King, R. G., Growth and function of the normal human placenta. Thromb. Res. 2004, 114, 397-407.
45. Wingren, C., Borrebaeck, C. A. K., Antibody microarrays - current status and key technological advances. OMICS 2006, 10, 411-427.
46. Wingren, C., Ingvarsson, J., Dexlin, L., Szul, D., Borrebaeck, C. A. K., Design of recombinant antibody microarrays for complex proteome analysis: choice of sample labeling-tag and solid support. Proteomics 2007, 7, 3055-3065.
47. Ingvarsson, J., Larsson, A., Sjoholm, A. G., Truedsson, L. et al., Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J. Prot. Res. 2007, 6, 3527-3536.
48. Angenendt, P., Progress in protein and antibody microarray technology. Drug Discov. Today 2005, 10, 503-511.
49. Kusnezow, W., Banzon, V., Schroder, C., Schaal, R. et al., Antibody microarray-based profiling of complex specimens: systematic evaluation of labeling strategies. Proteomics 2007, 7, 1786-1799.
50. Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P. et al., Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur. J. Cancer 2008, 44, 472-480.
51. Ingvarsson, J., Wingren, C., Carlsson, A., Ellmark, P. et al., Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008, 8, 2211-2219.
52. Orchekowski, R., Hamelinck, D., Li, L., Gliwa, E. et al., Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res. 2005, 65, 11193-11202.
53. Shafer, M. W., Mangold, L., Partin, A. W., Haab, B. B., Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease. Prostate 2007, 67, 255-267.
54. Sanchez-Carbayo, M., Socci, N. D., Lozano, J. J., Haab, B. B., Cordon-Cardo, C., Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 2006, 168, 93-103.
55. Srivastava, M., Eidelman, O., Jozwik, C., Paweletz, C. et al., Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol. Genet. Metab. 2006, 87, 303-310.
56. Madan, M., Bishayi, B., Hoge, M., Messas, E., Amar, S., Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis 2007, 190, 62-72.
57. Cai, M., Yin, W., Li, Q., Liao, D. et al., Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs. Eur. J. Pharmacol. 2006, 540, 139-146.
58. Sharma, M., Arnason, J. T., Burt, A., Hudson, J. B., Echinacea extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells. Phytother. Res. 2006, 20, 147-152.
59. Steinhauer, C., Wingren, C., Hager, A. C., Borrebaeck, C. A. K., Single framework recombinant antibody fragments designed for protein chip applications. Biotechniques 2002, 33, 38-45.
60. Wingren, C., Steinhauer, C., Ingvarsson, J., Persson, E. et al., Microarrays based on affinity-tagged single-chain Fv antibodies: sensitive detection of analyte in complex proteomes. Proteomics 2005, 5, 1281-1291.
61. Borrebaeck, C. A. K., Wingren, C., Transferring proteomic discoveries into clinical practice. Exp. Rev. Proteomics 2009, 6, 11-13.
62. Borrebaeck, C. A. K., Wingren, C., Design of high-density antibody microarrays for disease proteomics: key technological issues. J. Proteomics 2009, 72, 928-935.
63. Wingren, C., Borrebaeck, C. A., Progress in miniaturization of protein arrays - a step closer to high-density nanoarrays. Drug Discov. Today 2007, 12, 813-819.
64. Ellmark, P., Ingvarsson, J., Carlsson, A., Lundin, B. S. et al., Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol. Cell. Proteomics 2006, 5, 1638-1646.
65. Dexlin, L., Ingvarsson, J., Frendeus, B., Borrebaeck, C. A. K., Wingren, C., Design of recombinant antibody microarrays for cell surface membrane proteomics. J. Prot. Res. 2008, 7, 319-327.
66. Lundberg, K., Lindstedt, M., Larsson, K., Dexlin, L. et al., Augmented Phl p 5-specific Th2 response after exposure of dendritic cells to allergen in complex with specific IgE compared to IgG1 and IgG4. Clin. Immunol. 2008, 128, 358-365.
67. Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N. et al., Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 2002, 8, 1383-1389.
68. Persson, P. H., Weldner, B. M., Normal range growth curves for fetal biparietal diameter, occipito frontal diameter, mean abdominal diameters and femur length. Acta Obstet. Gynecol. Scand. 1986, 65, 759-761.
69. Persson, P. H., Weldner, B. M., Intra-uterine weight curves obtained by ultrasound. Acta Obstet. Gynecol. Scand. 1986, 65, 169-173.
70. Wingren, C., Borrebaeck, C. A. K., Antibody microarray analysis of directly labelled complex proteomes. Curr. Opin. Biotechnol. 2008, 19, 55-61.
71. Soderlind, E., Strandberg, L., Jirholt, P., Kobayashi, N. et al., Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat. Biotechnol. 2000, 18, 852-856.
72. Eisen, M. B., Spellman, P. T., Brown, P. O., Botstein, D., Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 1998, 95, 14863-14868.
73. Wang, C. C., Yim, K. W., Poon, T. C., Choy, K. W. et al., Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin. Chem. 2007, 53, 42-52.
74. Sood, R., Zehnder, J. L., Druzin, M. L., Brown, P. O., Gene expression patterns in human placenta. Proc. Natl. Acad. Sci. USA 2006, 103, 5478-5483.
75. Azizieh, F., Raghupathy, R., Makhseed, M., Maternal cytokine production patterns in women with pre-eclampsia. Am. J. Reprod. Immunol. 2005, 54, 30-37.
76. Lukanov, T. H., Bojinova, S. I., Emin, A. L., Veleva, G. L. et al., Upregulation of the CD40-CD40 ligand system in pre-eclampsia. Int. J. Gynecol. Obstet. 2009, 105, 257-260.
77. Lukanov, T. H., Bojinova, S. I., Popova, V. S., Emin, A. L. et al., Flow cytometric investigation of CD40-CD40 ligand system in preeclampsia and normal pregnancy. Clin. Appl. Thromb. Hemost. 2010, 16, 306-312.
78. Saito, S., Umekage, H., Sakamoto, Y., Sakai, M. et al., Increased T-helper-1-type immunity and decreased T-helper-2-type immunity in patients with preeclampsia. Am. J. Reprod. Immunol. 1999, 41, 297-306.
79. Bachour, A., Teramo, K., Hiilesmaa, V., Maasilta, P., Increased plasma levels of inflammatory markers and upper airway resistance during sleep in pre-eclampsia. Sleep Med. 2008, 9, 667-674.
80. Jonsson, Y., Ruber, M., Matthiesen, L., Berg, G. et al., Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J. Reprod. Immunol. 2006, 70, 83-91.
81. Challis, J. R., Lockwood, C. J., Myatt, L., Norman, J. E. et al., Inflammation and pregnancy. Reprod. Sci. 2009, 16, 206-215.
82. Wilczynski, J. R., Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia - the same basic mechanism? Hum. Immunol. 2006, 67, 492-511.
83. Elsmen, E., Kallen, K., Marsal, K., Hellstrom-Westas, L., Fetal gender and gestational-age-related incidence of pre-eclampsia. Acta Obste. Gynecol. Scand. 2006, 85, 1285-1291.